CASE REPORTS

Organizing Pneumonia Associated With the Use of Pegylated Interferon Alfa

Joan-Carles Trullas Vila, Demetrio-Roberto Padilla López, Vicenta Bisbe Company, Silvia Soler Simón, Pere Cortés Hausmann, and Josep Bisbe Company

Servicio de Medicina Interna, Hospital Sant Jaume, Olot, Girona, Spain

Organizing pneumonia is a well-differentiated clinical and histologic entity whose onset is usually subacute with respiratory symptoms and pulmonary infiltrates. Its origin may be unknown (cryptogenic) or it may be associated with various medical conditions, infectious diseases, or drugs. Diagnosis is confirmed by the presence of foci of organizing pneumonia in lung biopsy specimens. Our patient was a 49-year-old man infected with the hepatitis C virus who was receiving pegylated interferon alfa-2b. He presented with dry cough, fever, dyspnea, and ground glass pulmonary infiltrates. After an open lung biopsy, he was diagnosed with organizing pneumonia. When pegylated interferon was discontinued and corticosteroids started, the symptoms and pulmonary infiltrates disappeared. To our knowledge, this is the second report of organizing pneumonia related to pegylated interferon alfa-2b.

Key words: Organizing pneumonia. Interferon alfa-2b. Hepatitis C.

Introduction

Organizing pneumonia is an interstitial pulmonary disease that has been well described for more than 20 years. Its origin may be unknown (cryptogenic) or it may be associated with various diseases or drugs. We report the case of a patient infected by the hepatitis C virus (HCV) who, after 6 months of therapy with pegylated interferon alfa-2b, presented with subacute dry cough, fever, and dyspnea on exertion. After open lung biopsy, he was diagnosed with organizing pneumonia. We carried out a thorough MEDLINE search (1976-2006) with the key words interferon alpha-2b, bronchiolitis obliterans organizing pneumonia, and hepatitis C. A search of the Pneumotox2 web page revealed that, to date, there has only been 1 case of organizing pneumonia associated with the treatment of hepatitis C using pegylated interferon alfa-2b.

Our patient was a 49-year-old man, ex-smoker with no known allergies, who was diagnosed with chronic HCV infection (genotype 1b) as the result of an analysis made before blood donation when he was 35 years old. Because of his persistently high transaminase levels (aspartate aminotransferase and alanine aminotransferase between 50 U/L and 100 U/L) and plasma viral load (number of copies of HCV RNA), the patient began treatment with subcutaneous pegylated interferon alfa-2b (1.5 µg/kg/week) and oral ribavirin (1000 mg/day) 6 months before admission. The patient showed good initial tolerance and adherence and it was not necessary to reduce the dose, as there were no adverse effects. The patient consulted with a 2-week history of persistent dry cough, fever, and progressive dyspnea that appeared even after minimal effort. The vital signs on admission were as follows: blood pressure 91/65 mm Hg, respiratory rate of 32 breaths/min, heart rate of 87 beats/min, and axillary temperature of 36ºC. The most remarkable findings of the physical examination were coarse crackles at the bases of both lungs; the remainder of the examination was normal. The findings of arterial gas analysis (inspired oxygen fraction of 0.21, pH of 7.42, PaCO2 of 62 mm Hg, PaO2 of 34 mm Hg, HCO3 of 22 mmol/L) and a chest radiograph (Figure) led us to recommend admission for further study and treatment. A standard workup during admission revealed the following values: erythrocyte sedimentation rate 24 mm/h, normal complete blood count, general biochemical parameters

Correspondence: Dr J.C. Trullas Vila
Servei de Medicina Interna, Hospital Sant Jaume
Mulleras, 15
17800 Olot, Girona, Spain
E-mail: jctruallas@hospiolot.com

Manuscript received April 13, 2007. Accepted for publication April 24, 2007.

Arch Bronconeumol. 2008;44(3):173-4 173
organizing pneumonia in samples obtained by transbronchial or surgical biopsy. The condition may arise from any of a number of conditions, including infection, aspiration pneumonia, inhalation of toxic substances, drug toxicity (caused by agents such as bleomycin, ergot derivatives, nitrofurantoin, phenytoin, amiodarone, carbamazepine, cyclophosphamide),2,3 radiotherapy, collagen diseases, vasculitis, or intestinal inflammatory diseases. When no associated disorder can be identified, this disease is known as cryptogenic organizing pneumonia.1,4 Pegylated interferon α-2b is a treatment that is being applied ever more broadly. It is used not only against HCV infection but also in such other diseases as multiple sclerosis. Physicians should therefore be aware of its side effects, the most frequent of which include psychiatric, hemolactic, and flu-like symptoms.6 Less common is pulmonary toxicity, which has usually occurred in cases of sarcoidosis7 and interstitial pneumonitis.8 There have been exceptional reports of eosinophilic pneumonia, asthma, and pleural effusion.2,3 Our patient had a 2-month history of dry cough, dyspnea, and fever. Chest auscultation revealed dry crackles and predominantly interstitial pulmonary infiltrates mainly at the bases of the lungs. The negative results of microbiology, the lack of response to antibiotic therapy, and the rapid response to corticosteroids led to a diagnosis of organizing pneumonia, which was confirmed by lung biopsy. When pegylated interferon α-2b was withdrawn and treatment with corticosteroids started, both symptoms and pulmonary infiltrates disappeared. This and the absence of another medical condition or other drugs that could be associated with organizing pneumonia led us to conclude that pegylated interferon α-2b can cause this disorder, although no cause-effect relationship has been demonstrated. To our knowledge, after the literature search mentioned above, this is the second case report of organizing pneumonia associated with pegylated interferon α-2b.

REFERENCES